BR112014019402A2 - - Google Patents

Info

Publication number
BR112014019402A2
BR112014019402A2 BR112014019402A BR112014019402A BR112014019402A2 BR 112014019402 A2 BR112014019402 A2 BR 112014019402A2 BR 112014019402 A BR112014019402 A BR 112014019402A BR 112014019402 A BR112014019402 A BR 112014019402A BR 112014019402 A2 BR112014019402 A2 BR 112014019402A2
Authority
BR
Brazil
Application number
BR112014019402A
Other languages
Portuguese (pt)
Other versions
BR112014019402A8 (pt
BR112014019402B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112014019402A2 publication Critical patent/BR112014019402A2/pt
Publication of BR112014019402A8 publication Critical patent/BR112014019402A8/pt
Publication of BR112014019402B1 publication Critical patent/BR112014019402B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112014019402-5A 2012-02-09 2013-01-14 Composto 2-aril-benzofuran-7-carboxamida, ou sal farmacologicamente aceitável do mesmo e método para a preparação do composto BR112014019402B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210028895.0A CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN201210028895.0 2012-02-09
PCT/CN2013/070410 WO2013117120A1 (zh) 2012-02-09 2013-01-14 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Publications (3)

Publication Number Publication Date
BR112014019402A2 true BR112014019402A2 (cg-RX-API-DMAC7.html) 2017-06-20
BR112014019402A8 BR112014019402A8 (pt) 2017-07-11
BR112014019402B1 BR112014019402B1 (pt) 2020-12-15

Family

ID=48922178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019402-5A BR112014019402B1 (pt) 2012-02-09 2013-01-14 Composto 2-aril-benzofuran-7-carboxamida, ou sal farmacologicamente aceitável do mesmo e método para a preparação do composto

Country Status (8)

Country Link
US (1) US9533965B2 (cg-RX-API-DMAC7.html)
EP (1) EP2813495B1 (cg-RX-API-DMAC7.html)
JP (1) JP5926821B2 (cg-RX-API-DMAC7.html)
CN (1) CN103242273B (cg-RX-API-DMAC7.html)
BR (1) BR112014019402B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863988C (cg-RX-API-DMAC7.html)
RU (1) RU2583900C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013117120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
CN105272936B (zh) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途
CN109134409B (zh) 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康(上海)健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
EP4682143A1 (en) 2023-03-10 2026-01-21 Convalife Pharmaceuticals Co., Ltd. Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87451A0 (en) 1987-09-04 1989-01-31 Tanabe Seiyaku Co Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
JP2002515488A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) * 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 2−フェニルベンズイミダゾールおよび2−フェニルインドール、その製造方法ならびに使用
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
DE10351315A1 (de) 2003-10-31 2005-06-16 Aventis Pharma Deutschland Gmbh 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
JP2010518146A (ja) 2007-02-16 2010-05-27 グラクソ グループ リミテッド ベンゾフラン化合物
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
GB0806656D0 (en) 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
US8569336B2 (en) * 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用

Also Published As

Publication number Publication date
RU2014132159A (ru) 2016-03-27
CN103242273B (zh) 2015-06-03
BR112014019402A8 (pt) 2017-07-11
US20150018542A1 (en) 2015-01-15
WO2013117120A1 (zh) 2013-08-15
RU2583900C2 (ru) 2016-05-10
BR112014019402B1 (pt) 2020-12-15
EP2813495A4 (en) 2015-06-17
JP5926821B2 (ja) 2016-05-25
JP2015511942A (ja) 2015-04-23
EP2813495B1 (en) 2016-09-28
CA2863988A1 (en) 2013-08-15
CA2863988C (en) 2016-03-22
US9533965B2 (en) 2017-01-03
CN103242273A (zh) 2013-08-14
EP2813495A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
BR112014019015A2 (cg-RX-API-DMAC7.html)
BR112014017784A2 (cg-RX-API-DMAC7.html)
BR112014017625A2 (cg-RX-API-DMAC7.html)
BR112014017659A2 (cg-RX-API-DMAC7.html)
BR112014017607A2 (cg-RX-API-DMAC7.html)
BR112014017646A2 (cg-RX-API-DMAC7.html)
BR112014017638A2 (cg-RX-API-DMAC7.html)
AR092201A1 (cg-RX-API-DMAC7.html)
BR112014018560A2 (cg-RX-API-DMAC7.html)
BR112013027865A2 (cg-RX-API-DMAC7.html)
BR112014017644A2 (cg-RX-API-DMAC7.html)
BR112014017634A2 (cg-RX-API-DMAC7.html)
BR112014017647A2 (cg-RX-API-DMAC7.html)
BR112014013184A8 (cg-RX-API-DMAC7.html)
BR112014017618A2 (cg-RX-API-DMAC7.html)
BR112014017627A2 (cg-RX-API-DMAC7.html)
BR112014017623A2 (cg-RX-API-DMAC7.html)
BR112014017652A2 (cg-RX-API-DMAC7.html)
BR112014017630A2 (cg-RX-API-DMAC7.html)
BR112014019357A2 (cg-RX-API-DMAC7.html)
BR112014017621A2 (cg-RX-API-DMAC7.html)
BR112014017631A2 (cg-RX-API-DMAC7.html)
BR112014019573A2 (cg-RX-API-DMAC7.html)
BR112014018670A2 (cg-RX-API-DMAC7.html)
BR112014017671A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2013, OBSERVADAS AS CONDICOES LEGAIS.